# Coherus Oncology to Share Interim Tagmokitug Clinical Data on October 28

- URL: https://stocks.freetheai.org/news/coherus-oncology-to-share-interim-tagmokitug-clinical-data-on-october-28-a721e2
- Published: 2026-10-14T20:30:00Z
- Category: company_news; sentiment: neutral; impact: medium
- Symbols: [NASDAQ:CHRS](https://stocks.freetheai.org/symbols/NASDAQ-CHRS)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Coherus Oncology, Inc. (NASDAQ:CHRS) plans to release interim clinical data for its tagmokitug development program on Wednesday, October 28, 2026. Executive management will host a live webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to review the results, joined by key opinion leaders who will provide expert clinical context.

Tagmokitug is an experimental cytolytic CCR8 antibody currently undergoing Phase 1b/2a clinical trial testing in combination with toripalimab, the company's approved PD-1 inhibitor marketed as LOQTORZI. The drug candidate is being studied as a potential treatment for multiple advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancers.

Investors and healthcare researchers can follow the presentation via a webcast hosted on the company's investor relations website, where accompanying presentation materials will be posted after the event. Stock in Coherus Oncology was trading at $1.05 per share following the announcement.

## Key points

- Coherus Oncology will release interim clinical data for its experimental drug tagmokitug on October 28, 2026.
- Tagmokitug is a selective cytolytic anti-CCR8 antibody in Phase 1b/2a trials for advanced solid tumors.
- The study evaluates tagmokitug combined with toripalimab, an approved PD-1 inhibitor marketed as LOQTORZI.
- Company management will host a webcast from 4:30 p.m. to 6:00 p.m. EDT with clinical insights from key opinion leaders.

## Questions and answers

### When will Coherus Oncology release the interim tagmokitug clinical data?

Coherus Oncology will share the interim data on Wednesday, October 28, 2026, during a webcast scheduled from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time.

### What is tagmokitug and how is it being tested?

Tagmokitug is an experimental cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies, evaluated alongside toripalimab in patients with various advanced solid tumors.

### How can investors access the Coherus Oncology webcast?

Investors can pre-register for dial-in access or listen to the live and archived webcast on the Investor Relations section of the Coherus Oncology website.